
AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOeGRoQWZMLXdrZmQ2ZG5OMlJlWnh3RDJUc3BOc2VWVk8yd3l1MS05aFFvUkJQYkJNbTNxMUZvbDlfcUozMlZpV3N4aGhEaksyUXh1OHpoVkszTXlaeGs3aTAwWDAtZEJzX0twQkx3eUxGaElnMS1qLS1jUXo3YTlpTnR5Mll2RVN2T2diTlZQU1d3OHdBMHNueHdmbEg2d0dQUDQyRm9xeTVuM08yb2twWGloS0x0dWJSei1lTmhaOTNMdTho?oc=5" target="_blank">AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Pharma</font>
